16 completed, 7 unknown, 3 terminated. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Completed 16, Unknown 7, Terminated 3 |
Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IV Iron-induced Hypophosphatemia After RYGB Iron isomaltoside, Iron Carboxymaltose - Hypophosphatemia, Roux-en-Y Gastric Bypass | Phase 4 | Unknown | Lucie Favre | 94 | 2024-05-02 | 2024-08-20 |
| Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients Cholestyramine Resin 4000 MG [Questran], Calcium Carbonate 500 MG Oral Tablet - Chronic Kidney Diseases, Hemodialysis Complication | Phase 4 | Completed | Ain Shams University | 80 | 2023-03-30 | 2024-08-06 |
| Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia Verum, Placebo - Anemia, Iron-deficiency | Phase 4 | Completed | Donat R. Spahn | 92 | 2021-11-11 | 2023-05-24 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 28 | 2021-11-01 | 2024-07-09 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 18 | 2021-09-28 | 2024-07-09 |
| Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy - Hyperphosphatemia, Anemia, Iron Deficiency | Phase 4 | Completed | USRC Kidney Research | 214 | 2021-06-29 | 2022-11-07 |
| Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Tenapanor - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 4 | Completed | Ardelyx | 333 | 2020-11-20 | 2023-03-29 |
| Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU Glycophos (Sodium Glycerophosphate), Antibiotics, Inotropes - Hypophosphatemia | Phase 4 | Unknown | Ain Shams University | 100 | 2020-09-15 | 2020-08-20 |
| Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Sucroferric Oxyhydroxide Chewable Tablet - Peritoneal Dialysis Complication, Hyperphosphatemia | Phase 4 | Completed | University of Colorado, Denver | 17 | 2020-02-01 | 2022-08-31 |
| Examining the Effect of Burosumab on Muscle Function Burosumab Injection [Crysvita] - X-linked Hypophosphatemia | Phase 4 | Completed | Yale University | 10 | 2019-11-13 | 2023-08-24 |
| A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Tenapanor, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 4 | Completed | Ardelyx | 172 | 2019-06-15 | 2023-03-29 |
| Burosumab in Children and Adolescents With X-linked Hypophosphatemia Burosumab Injection - Rare Diseases, X-linked Hypophosphatemia | Phase 4 | Unknown | Bicetre Hospital | 57 | 2018-03-18 | 2020-06-05 |
| The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Niacin, Phosphate Binder - Hyperphosphatemia | Phase 4 | Unknown | Assiut University | 150 | 2017-06-01 | 2017-05-23 |
| Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Ferric Citrate - Hyperphosphatemia | Phase 4 | Completed | Kaiser Permanente | 55 | 2017-05-01 | 2022-01-13 |
| Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Ferric Citrate - Kidney Failure, Chronic, End-stage Renal Disease | Phase 4 | Completed | Panion & BF Biotech Inc. | 202 | 2017-04-12 | 2020-01-13 |
| Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia Calcitriol - X-linked Hypophosphatemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 100 | 2017-01-01 | 2019-01-30 |
| Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Nicotinic Acids, Calcium Carbonate - Hyperphosphatemia | Phase 4 | Unknown | Jiujiang No.1 People's Hospital | 45 | 2016-07-01 | 2016-08-30 |
| A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Ferric Citrate - End Stage Renal Disease, Hyperphosphatemia | Phase 4 | Terminated | Winthrop University Hospital | 38 | 2015-07-01 | 2023-04-20 |
| Phosphate Lowering in CKD Trial Lanthanum carbonate, placebo, Ascorbic Acid - Chronic Kidney Disease, Cardiovascular Disease | Phase 4 | Completed | VA Office of Research and Development | 66 | 2014-09-15 | 2022-08-26 |
| Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Lanthanum carbonate, Calcium Carbonate - Renal Insufficiency, Chronic, Hyperphosphatemia | Phase 4 | Unknown | Osaka University | 60 | 2014-09-01 | 2021-02-25 |
Showing 20 of 26. Sign in to see all of them.
Hyperphosphatemia (18) · Familial Hypophosphatemic Rickets (5) · Kidney Failure, Chronic (4) · Renal Insufficiency (4) · Renal Insufficiency, Chronic (4) · Hyperparathyroidism, Secondary (3) · Hypophosphatemia (3) · Anemia, Iron-Deficiency (2) · Hypercalcemia (2) · Kidney Diseases (2) · Anemia (1) · Arteriosclerosis (1) · Bone Diseases, Metabolic (1) · Calcinosis (1) · Cardiovascular Diseases (1)
Nutritional and Metabolic Diseases (26) · Metabolic Diseases (25) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Male Urogenital Diseases (16) · Urogenital Diseases (16) · Urologic Diseases (15) · Kidney Diseases (14) · Calcium Metabolism Disorders (9) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Chronic Disease (7) · Bone Diseases (6)
Calcium Carbonate (4) · burosumab (4) · ferric citrate (4) · Sevelamer (3) · lanthanum carbonate (3) · Calcitriol (2) · Niacin (2) · calcium acetate (2) · paricalcitol (2) · tenapanor (2) · Anti-Bacterial Agents (1) · Ascorbic Acid (1) · Atorvastatin (1) · Cholestyramine Resin (1) · Nicotinic Acids (1)
Ain Shams University (2) · Ardelyx (2) · Kyowa Kirin Co., Ltd. (2) · Winthrop University Hospital (2) · Assiut University (1) · Bicetre Hospital (1) · Chugai Pharma Taiwan (1) · Donat R. Spahn (1) · Fresenius Medical Care North America (1) · Jiujiang No.1 People's Hospital (1) · Kaiser Permanente (1) · Lucie Favre (1) · Nabi Biopharmaceuticals (1) · Osaka University (1) · Panion & BF Biotech Inc. (1)
United States (11) · China (4) · Switzerland (2) · Austria (1) · Belgium (1) · Denmark (1) · Egypt (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Taiwan (1)
Ahmed Kamal, Dr. (1) · Anna J Jovanovich, MD (1) · Candace Grant, MD (1) · Chiu-Ching Huang, Professor (1) · David P Rosenbaum, PhD (1) · Donat R Spahn, Prof. Dr. (1) · Efstathios Mitsopoulos, MD (1) · Jessica Kendrick, MD (1) · Karl L Insogna, M.D. (1) · Mai-Szu Wu, M.D. (1) · Peter Kotanko, MD (1) · Shayan Shirazian, MD (1) · Takayuki Hamano, MD, PhD (1)
PMID 40576086, PMID 37853560, PMID 38323855, PMID 18423809, PMID 23505057, PMID 26192787, PMID 27007989, PMID 28382661, PMID 35239732, PMID 35810296, PMID 38781013, PMID 38972306, PMID 39671753, PMID 39910709